Daniel Henderson

Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.

Ronald Rodríguez, Eric R. Schuur, Ho Yeong Lim et al. · PubMed · 1997 · 590 citations

Medicine, Molecular Biology, Oncology +14

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

Douglas Brand, Alison Tree, Peter Ostler et al. · The Lancet Oncology · 2019 · 536 citations · Full text

Medicine, Oncology, Radiation Oncology +17

A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.

Theodore L. DeWeese, H. Van der Poel, S. Li et al. · PubMed · 2001 · 386 citations

Medicine, Oncology, Radiation Oncology +16

Prostate-specific Antigen Expression Is Regulated by an Upstream Enhancer

Eric R. Schuur, Gail Henderson, Lena A. Kmetec et al. · Journal of Biological Chemistry · 1996 · 315 citations · Full text

Life Sciences, Molecular Biology, Molecular Genetics +11

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

Alison Tree, Peter Ostler, H. van der Voet et al. · The Lancet Oncology · 2022 · 303 citations · Full text

Medicine, Oncology, Radiation Oncology +16